DK1444261T3 - Immunogene ALK (anaplastisk lymfomakinase) peptider - Google Patents

Immunogene ALK (anaplastisk lymfomakinase) peptider

Info

Publication number
DK1444261T3
DK1444261T3 DK02787687T DK02787687T DK1444261T3 DK 1444261 T3 DK1444261 T3 DK 1444261T3 DK 02787687 T DK02787687 T DK 02787687T DK 02787687 T DK02787687 T DK 02787687T DK 1444261 T3 DK1444261 T3 DK 1444261T3
Authority
DK
Denmark
Prior art keywords
alk
peptides
anaplastic lymphoma
lymphoma kinase
immunogenic
Prior art date
Application number
DK02787687T
Other languages
English (en)
Inventor
Carlo Gambacorti-Passerini
Lorena Passoni
Original Assignee
Ist Naz Stud Cura Dei Tumori
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ist Naz Stud Cura Dei Tumori filed Critical Ist Naz Stud Cura Dei Tumori
Application granted granted Critical
Publication of DK1444261T3 publication Critical patent/DK1444261T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4244—Enzymes
    • A61K40/4251—Kinases, e.g. Raf or Src
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK02787687T 2001-11-15 2002-11-14 Immunogene ALK (anaplastisk lymfomakinase) peptider DK1444261T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/008,377 US20030157101A1 (en) 2001-11-15 2001-11-15 Immunogenic ALK peptides

Publications (1)

Publication Number Publication Date
DK1444261T3 true DK1444261T3 (da) 2006-03-20

Family

ID=21731292

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02787687T DK1444261T3 (da) 2001-11-15 2002-11-14 Immunogene ALK (anaplastisk lymfomakinase) peptider

Country Status (9)

Country Link
US (1) US20030157101A1 (da)
EP (1) EP1444261B1 (da)
AT (1) ATE308565T1 (da)
AU (1) AU2002352011A1 (da)
CY (1) CY1105357T1 (da)
DE (1) DE60207103T2 (da)
DK (1) DK1444261T3 (da)
ES (1) ES2250727T3 (da)
WO (1) WO2003042243A2 (da)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4931154B2 (ja) * 2005-02-28 2012-05-16 オンコセラピー・サイエンス株式会社 血管内皮増殖因子受容体１に由来するエピトープ・ペプチドおよびこれらのペプチドを含むワクチン
EP2042191B1 (en) 2007-09-28 2013-01-02 Roberto Chiarle Anaplastic Lymphoma Kinase (ALK) as oncoantigen for lymphoma vaccination
WO2017132555A1 (en) * 2016-01-29 2017-08-03 Vedantra Pharmaceuticals, Inc. Alk polypeptides and methods of use thereof
WO2021055580A2 (en) * 2019-09-18 2021-03-25 Children's Medical Center Corporation An anaplastic lymphoma kinase (alk) cancer vaccine and methods of use

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4877611A (en) * 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US5529925A (en) * 1993-12-03 1996-06-25 St. Jude Children's Research Hospital Nucleic acid sequences and fusion proteins present in human t(2;5) lymphoma

Also Published As

Publication number Publication date
ATE308565T1 (de) 2005-11-15
US20030157101A1 (en) 2003-08-21
CY1105357T1 (el) 2010-03-03
WO2003042243A3 (en) 2004-03-25
WO2003042243A2 (en) 2003-05-22
AU2002352011A1 (en) 2003-05-26
ES2250727T3 (es) 2006-04-16
DE60207103T2 (de) 2006-10-05
DE60207103D1 (en) 2005-12-08
EP1444261A2 (en) 2004-08-11
EP1444261B1 (en) 2005-11-02

Similar Documents

Publication Publication Date Title
AU2003242305A1 (en) Hla-a24-restricted cancer antigen peptide
MY136095A (en) Use of human anti-ctla-4 antibodies for treatment of cancer
HUP0203968A2 (hu) Készítmények és eljárások prosztatarák terápiájára és diagnózisára
DK1468014T3 (da) Sammensætninger og fremgangsmåder til WT1-specifik immunterapi
IL125590A (en) Peptide immunogens, process for their preparation and use thereof as vaccines against allergies
AU2002359727A1 (en) Fused cyclic modulators of nuclear hormone receptor function
MXPA04006271A (es) Derivados de indolinona utiles como inhibidores de la proteina cinasa.
CY1114643T1 (el) Νεοπλασματικες κυτταρικες σειρες nm-f9 (dsm acc2606) και nm-d4 (dsm acc2605), χρησεις αυτων
IL153680A0 (en) Aplidine derivatives and methods for the preparation thereof
UA85365C2 (ru) Продукт конъюгирования цитокина для использования в противораковой терапии
AU2003267401A1 (en) Novel mhc ii associated peptides
ATE551069T1 (de) Mucin-fusionspolypeptid-vakzine, zusammensetzungen und ihre verwendung
DK0889969T3 (da) Rekombinante adenovirale til genterapi af humane tumorer
ATE371031T1 (de) Herpes-simplex virus, das das gen von interleukin-12 exprimiert, und dessen verwendung zur behandlung von krebs
WO2006023598A3 (en) Prostate-specific antigen-derived mhc class ii-restricted peptides and their use in vaccines to treat or prevent prostate cancer
DK1444261T3 (da) Immunogene ALK (anaplastisk lymfomakinase) peptider
WO2003093298A3 (en) Immunogenic peptides
WO2000052045A3 (en) Mage-3 derived immunogenic peptides presented by mhc of class ii and the use thereof
MXPA03005031A (es) Composicion vacunal que contiene factor de crecimiento transformante alfa.
DK1578772T3 (da) Cytokiner og cytokinreceptorer med reduceret immunogenicitet
MY127452A (en) Vaccines.
CY1105179T1 (el) Φαρμακα για την ανοσοθepαπεια κακοηθων ογκων
DK0996636T3 (da) HA-1-antigenet
UY26170A1 (es) Antigeno (c42) asociados a tumores
AU2003214645A1 (en) Long pentraxin ptx3 functional derivatives for preparing an autologous vaccine for the treatment of tumours